P130 - Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α 4β 7 integrin
A. Parikh(Takeda (United States)), Irving H. Fox(Takeda (United States)), Vivek J. Kadambi, D. Soler, T. Wyant, Catherine Milch(Millennium Engineering and Integration (United States)), Timothy Leach(Takeda (United States)), Eric R. Fedyk(Takeda (United States))
Cited by 1
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694